BLA 103767 · Eisai INC
Ontak
Denileukin Diftitox
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 10, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Feb 5, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
48
0 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2008 Supplement 5094 · Efficacy · priority review OrphanLabelLetter
- Feb 5, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
1 products under this application
- ONTAK · DENILEUKIN DIFTITOX 150UG/ML · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Denileukin Diftitox" as an intervention, any sponsor and status, largest first.
- Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00050999 · 195 participants · Start Jun 1995 · Primary completion Sep 2006
Drug: ONTAK · For: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome
Sites: Houston, Texas; Saint Leonard's, Australia; Westmead, Australia · 35 sites in all
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00224874 · 180 participants · Start Sep 2005 · Primary completion Jan 2009
Drug: Etanercept; Mycophenolate Mofetil and 2 more · For: Graft vs Host Disease; Immune System Disorders
Sites: Duarte, California; San Diego, California; Stanford, California · 19 sites in all
- Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsCompleted
Eisai Inc.Eisai
NCT00051012 · 86 participants · Start Sep 1995 · Primary completion Oct 2006
Drug: ONTAK · For: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome
Sites: Houston, Texas; Saint Leonard's, Australia; Westmead, Australia · 34 sites in all
Eastern Cooperative Oncology GroupResearch network
NCT00003615 · 77 participants (planned) · Start May 20, 1999 · Primary completion Aug 2006
Drug: denileukin diftitox · For: Lymphoma
Sites: Chicago, Illinois; Boston, Massachusetts; Las Vegas, Nevada · 10 sites in all
Eisai Inc.Eisai
NCT01127451 · 75 participants · Start Jun 22, 2010 · Primary completion Apr 7, 2015
Drug: Denileukin diftitox · For: Stage IIIC Melanoma; Stage IV Melanoma
Sites: Encinitas, California; Los Angeles, California; Washington D.C., District of Columbia · 10 sites in all
James Graham Brown Cancer CenterAcademic, hospital or other
NCT00299689 · 69 participants · Start Mar 2006 · Primary completion Jan 2010
Drug: Denileukin diftitox · For: Malignant Melanoma
Sites: Louisville, Kentucky
Eisai Inc.Eisai
NCT00211198 · 60 participants · Start May 2001 · Primary completion Jan 2005
Drug: ONTAK (denileukin difitox, DAB389IL-2) · For: Lymphoma, T-Cell, Cutaneous
Sites: Duarte, California; New Haven, Connecticut; Iowa City, Iowa · 9 sites in all
Eisai Inc.Eisai
NCT00211276 · 50 participants (planned) · Start Mar 2005 · Primary completion Jan 2007
Drug: ONTAK (denileukin diftitox) · For: Lymphoma, B-Cell
Sites: Beverly Hills, California; Fountain Valley, California; Los Angeles, California · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Foss FM, Kim YH, Prince HM, et al. · J Clin Oncol 2025 · Multicenter Study, Clinical Trial, Phase III
- Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Liao JB, Jejurikar NS, Hitchcock-Bernhardt KM, et al. · Gynecol Oncol 2024 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
Prince HM, Duvic M, Martin A, et al. · J Am Acad Dermatol 2012 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
Prince HM, Martin AG, Olsen EA, et al. · Leuk Lymphoma 2013 · Clinical Trial, Multicenter Study
- Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control.
Grzywacz B, Moench L, McKenna D, et al. · J Immunother 2019 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.